Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

TCTMD’s Top 10 Most Popular Stories for June 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

June 28, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

News Conference News ESC Heart Failure 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

May 26, 2019

Coping With CABANA: Despite Trial Flaws, A-fib Experts Say Lessons Have Been Learned

News Conference News EHRA 2019

Coping With CABANA: Despite Trial Flaws, A-fib Experts Say Lessons Have Been Learned

March 26, 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

News Conference News EHRA 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

March 21, 2019

For Acute A-fib, Wait-and-See Approach May Spare Many Patients From Cardioversion

News Conference News EHRA 2019

For Acute A-fib, Wait-and-See Approach May Spare Many Patients From Cardioversion

March 18, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.